Key Takeaways STELLAR-303 met a primary endpoint, showing OS gains with zanzalintinib plus Tecentriq in mCRC.STELLAR-304 completed enrollment in advanced non-clear cell renal cell carcinoma patients.Phase III STELLAR-311 began, testing zanzalintinib versus everolimus in advanced neuroendocrine tumors.Exelixis ((EXEL) is developing zanzalintinib — a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhibits the activity of receptor tyrosine kinases implicated in cancer growth and s ...